CCI

CompletedPhase NA

CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia

CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia: Depression, Anxiety, and Mild Cognitive Impairment

Lead sponsor

Centre for Addiction and Mental Health

Assets

Sertraline / Venlafaxine

Listed sites

Recruiting sites

Enrollment

145

actual

Study population

Mixed / unspecified dementia

Key I/E criterion

•Age 60-65

Primary endpoint

•Anxiety/depression/quality of life (QOL) scores among participants in the ICP

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID019/2016

NCT IDNCT02955719

Timeline

Milestones

Study start2016-03-30actual

Study first posted2016-11-04estimated

Primary completion2020-07-16actual

Study completion2020-07-16actual

Last update posted2021-01-07actual

Assets

Drug assets

Sertraline Venlafaxine

Study populations

Who this study enrolls

Mixed / unspecified dementia

Eligibility

Who can enroll

Minimum age60 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

1. Female or male primary practice patients of participating physicians born in 1951, 1953 or 1955 (ICP) and 1950, 1952 or 1956 (TAU).

2. Can read and understand English.

3. Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice.

4. Willing and able to provide informed consent

Exclusion criteria

1. Diagnosis of dementia.

2. Substance abuse identified as an acute problem in the four weeks before being enrolled in the study (i.e. the day the patient signs the informed consent form).

3. Those with delirium, or where we are unable to make a diagnosis of MCI, due to unstable comorbidities.

4. Palliative-care patients.

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Behavior / neuropsychiatric

Other clinical outcomes

Other (unclassified)

Behavior / neuropsychiatric

5 endpoints

Primary/protocol endpoint

Change in anxiety/depression/quality of life (QOL) scores among participants in the ICP and comparison groups

Time frame:From Baseline Screening to 24 month follow-up

change from baseline, improvement

Secondary/protocol endpoint

Changes in the primary care providers' knowledge of, and ability to recognize and manage, depression, anxiety, and MCI in older adults.

Time frame:Baseline to 24 month follow-up

descriptive

Secondary/protocol endpoint

Time-to-treatment initiation among those in the ICP arm versus those in the comparison arm.

Time frame:Baseline to 24 month followup

descriptive

Secondary/protocol endpoint

Specific Aim 3a: To assess the impact of the ICP on the rates of diagnoses/detection among older patients with anxiety, depression, or MCI compared to before ICP implementation.

Time frame:Calculate one year prior to the time of Site Initiation Visit for all recruiting sites.

categorical status, descriptive

Secondary/protocol endpoint

Specific Aim 3b: To assess the impact of ICP on rates of diagnoses/detection among patients of the same age cohort as our target ICP population, but not in our study sample.

Time frame:Calculate the 6 month period prior to the last study assessment for a given recruitment site.

categorical status, descriptive

Other clinical outcomes

2 endpoints

Secondary/protocol endpoint

Acceptability and perceived utility of the ICP

Time frame:Baseline to 24 month follow-up

descriptive

Secondary/protocol endpoint

Feasibility of the ICP

Time frame:Baseline to 24 month follow-up

descriptive

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Adjustments made for the adoption of the ICP in primary care teams

Time frame:Baseline to 24 month follow-up

descriptive

Secondary/protocol endpoint/low confidence

Barriers to implementation of the ICP and the key elements to initiate, sustain and spread the ICP

Time frame:Baseline to 24 month follow-up

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Kates N, Craven M; Collaborative Working Group of the College of Family Physicians of Canada, Canadian Psychiatric Association. Shared mental health care. Update from the Collaborative Working Group of the College of Family Physicians of Canada and the Canadian Psychiatric Association. Can Fam Physician. 2002 May;48:936. No abstract available.
PMID12053639via RESULT

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.